Pain relief from postherpetic neuralgia
Conditions
Interventions
Step1
Apply three investigational drugs to the back for 12 hours.
Blood is collected for measuring plasma drug concentration.
Step2
Three investigational drugs are applied to the back for 12 hours re
Sponsors
Taira Kayo
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) Japanese healthy adult male applicants aged between 20 and 45 at the time of consent acquisition 2) Those who have received sufficient explanation about the content of this clinical trial and obtained their written consent. 3) Persons weighing 50 kg or more at the time of screening test
Exclusion criteria
Exclusion criteria: 1) Those who have skin diseases or skin abnormalities (dermatitis, eczema, pimples, dyschromia, etc.) at the application site 2) Persons with a history of skin allergies (persons with hypersensitivity to transdermal preparations) 3) Persons who routinely use external preparations such as coating agents, patches, and aerosols on the application site 4) If there are disorders in the gastrointestinal tract, heart, liver, kidneys, blood, respiratory organs, etc. that are thought to affect pharmacokinetics and safety, or if their history interferes with clinical trial participation, judged by Principal investigator (Subinvestigator ) 5) Those who have hypersensitivity or idiosyncratic constitution to drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacokinetics Plasma NZT-235 concentration | — |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacodynamics safety | — |
Contacts
Public ContactMasato Kawanishi
Nippon Zoki pharmaceutical Co LTD
Outcome results
None listed